Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00292552 · ClinicalTrials.gov registry record
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints
A clinical trial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 2,747
- Enrollment target
NCT00292552: Completed study, sponsored by GlaxoSmithKline.
NCT00292552 is a clinical trial that has completed, run by GlaxoSmithKline. The registered enrollment target is 2,747 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00292552 has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 2,747 participants
- Enrollment target
Study Summary
This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.
Interventions
- OTHER Novel endpoint determination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,747 participants |
| Start Date | 2005-12 |
| Est. Completion | 2010-02 |
What the finished NCT00292552 record still lists
NCT00292552 is an observational study that tracks outcomes without assigning an intervention. Its 2,747 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Novel endpoint determination is the first listed.
NCT00292552 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00292552 about?
NCT00292552 is a clinical study titled "Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints". This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects ...
What is the current status of trial NCT00292552?
This trial is currently completed. The enrollment target is 2,747 participants. The study started on 2005-12. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00292552?
The interventions under investigation include: Novel endpoint determination (OTHER).
Who is sponsoring clinical trial NCT00292552?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06085833 · 2,706 participants · NA
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
- NCT04073420 · 2,700 participants
Medtronic Cardiac Surgery PMCF Registry
- NCT05125939 · 2,700 participants
Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study
- NCT05586776 · 2,700 participants · Phase 4
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia